Jorge Parodi

• Lead the OM Pharma Peruvian affiliate with full P&L responsibility, Sales and Marketing, IT, Finance, Medical, Regulatory Affairs/ Quality, HR, and Market Access, reporting to Headquarter in Geneva - Switzerland • Revitalization and relaunch of brands, optimizing geographic coverage nationwide, allowing sales to double from 2016 to 2019, exceeding USD 10.4MM and tripling contribution, leading a staff of 50 employees. • Successful re-launch of OM Pharma after losing 50% of the Iron Business and reducing to 21 employees. We closed 2021 + 33% above the Budget, exceeding pre-Covid sales levels and establishing a new historical peak in sales of USD 4.3MM, since 2011. • Successful negotiation with Grupo Farma (Due Diligence) for Colombia, Peru, and Ecuador for the exclusivity of the Iron Portfolio, with sales greater than USD 5MM, achieving upfront of USD 1.5MM for Vifor and relocation of 90% of commercial, medical, and marketing team. • Substantial improvement in the work environment by launching "Reward & Recognition" programs, talent integration and development, achieving productivity improvement, team integration, and reduction of the turnover ratio below 5%; the Emotional Salary was implemented.

Responsible for managing the Glenmark Pharmaceuticals operations in Peru and Ecuador, opening the new branch, registering products and trademarks, new product planning, sales budget, and managing the team and operations • Driving and implementing a new demand generation region that achieved sales of US$ 7.1 million and strong leadership in the dermatological, respiratory, and institutional market between Peru and Ecuador. • Achieving a dramatic growth in market share, and profits leading an staff of 54 employees

INNOVA SULPHATES Nov 2007– To date • Reorganized management and restructuration of the new brand Innova Sulphates. Responsible for an investment of US$ 6 million dollars related to all financial, budgeting, purchasing, operating forecast, cash flow planning, legal, regulatory, equipment management, cost/pricing, P&L, and related activities. • Responsible for the launching strategy to entering the sulphates market focusing on both, the agrochemicals and mining field with sales of US$ 8.2 million since its first year, and net profits of US$ 800 K dollars • Fully responsible for the manufacturing operations and commercial activities besides the design and launching of the new factory for the business lines of Copper, Zinc and Magnesium Sulphates, plus future business developments. Direct management supervision of Manufacturing, Logistics, QC, HR and Sales/exports.

Peruvian industrial company involved in the chemical, fishing and mining sector, with revenues of US$ 100 million and more than 350 employees. • Responsible for developing and designing the start-up strategy of introduction of Innova into the pharmaceutical market and the launching strategy of their own “brand portfolio” • This strategic senior role will be focused on assessing market drivers, trends, distribution channels, branding and licensing, sales force deployment, market strategies and identifying future opportunities for Innova and its manufacturing plant located in Lima

Overall responsibility for starting-up operations and leading all legal, administrative and commercial activities in the Ecuadorian market leading 29 employees. · Leading the process of designing and implementing a new demand generation center that achieved short-term profit of US$ 500 K since its first year under strong financial constraints. · Sales grew more than 100% achieving US$ 3.2 million, more than double of sales since operations started in the Ecuadorian market. · Leading a dramatic growth in market share. Lilly achieved position 46 in the ethical market; we moved from position 71 in year 2002, and got 0.51% share in cash.

Specialized in the development & alignment of marketing strategy for Zyprexa, a US$ 3.8 billion neuroscience product. Responsible for the management of both internal and external business partner relationships and coordination of communication processes · Responsible for the Publication and Communication Plan, a comprehensive new approach to how the Global Team communicates that received the “Zyprexa Radical Thinking Award” · Developed and implemented an intranet site as a tool for the Zyprexa brand, aligned global and affiliate communication process. Increased monthly unique visitors by 166% and return visitors by 50%. The intranet site, along with the communication process, were recognized as the “best intranet site” in 2002 across the Global Marketing & Sales Organization

Responsible for developing a business plan for Eli Lilly an Ache Laboratories, a US$ 600 million brasilean leading pharmaceutical company · A new model of co-promotion that moved into co-marketing was developed giving Ache the rights of taking the brand Evista at third year. Obtained local BOD approval and successfully negotiated licensing contract that raised Evista to an additional 250 sales force.

Regional Office specialized in strategic marketing and finance that provide support to Andean, Central-American, and Caribbean countries with total sales of US$ 80 million and 250 employees Neuroscience Regional Product Manager Responsible for the regional neuroscience portfolio, in charge of the brands PROZAC, ZYPREXA and CELANCE respectively in a potential regional market of US$ 40 million · Zyprexa achieved leadership in the Peruvian and Venezuelan markets respectively, sales grew 20% and with significant growth in the Colombian market · Designed and led the integration process of first regional marketing strategy that standardized and ordered the portfolio putting it back on a growth path in such markets.